Yersinia species as a model organism for studying bacterial evolution,[2]
how bacterial genetic variability can be used to track changes in bacterial populations,[3]
how lineages of COVID-19 can vary in their viral load,[4]
He has active collaborations in the UK, China, Germany, France, Vietnam, and the US.[5]
COVID-19 pandemic work
During the COVID-19 pandemic in the United Kingdom, McNally was seconded to the Milton KeynesLighthouse Labs as Infectious Disease lead at the Government’s first flagship COVID-19 testing facility. Launched on 9 April 2020, the Milton Keynes Lighthouse Lab was the first of three UK ‘mega-labs’ that vastly increased the testing capacity, allowing many more patient samples to be processed each day.[6]
References
^"Alan McNally". University of Birmingham. Retrieved 10 April 2024.
^McNally, Alan; Thomson, Nicholas R.; Reuter, Sandra; Wren, Brendan W. (March 2016). "'Add, stir and reduce': Yersinia spp. as model bacteria for pathogen evolution". Nature Reviews Microbiology. 14 (3): 177–190. doi:10.1038/nrmicro.2015.29. PMID26876035.